Purpose: The excision repair cross-complementing 1 (ERCC1) gene is coding for a nucleotide excision repair protein involved in the repair of radiation-and chemotherapy-induced DNA damage. We examined the potential of quantitative ERCC1 mRNA expression to predict minor or major histopathological response to neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil, and 36 Gy of radiation) followed by transthoracic en bloc esophagectomy in patients with locally advanced esophageal cancer (cT 2-4 , N x , M 0 ).
INTRODUCTION
Patients with locally advanced esophageal cancer have a dismal prognosis when treated exclusively by surgery. This fact prompted many investigators to apply neoadjuvant treatment strategies in an effort to improve survival (1) . Results from Phase III randomized trials are encouraging; however, they revealed that only patients with major histopathological response will finally benefit from treatment (2) (3) (4) . In addition, these therapies are expensive and potentially harmful with increased therapy-associated complication rates (5) . Therefore, predictive molecular markers indicating response or nonresponse to neoadjuvant treatment would be extremely helpful in selecting patients for future treatment protocols.
The nucleotide excision repair pathway is one of the most important pathways that guards the integrity of the genome, removing a wide variety of DNA lesions including interstrand cross-links caused by cisplatin (CDDP) or radiation (6, 7) . Removal of these adducts from genomic DNA is mediated by a complex interaction of various proteins (8, 9) . A critical step in this process is the interaction of the product of the excision repair cross-complementing 1 (ERCC1) gene with XPA and XPF (10) .
Metzger et al. (11) have reported increased ERCC1 mRNA expression as an indicator for nonresponse to neoadjuvant CDDP-based chemotherapy (CDDP, leucovorin, and 5-fluorou-racil) for gastric cancer. A correlation of increased ERCC1 expression with nonresponse and/or survival has also been reported recently for colon cancer (12) and non-small cell lung cancer (13) .
The purpose of this prospective study was to investigate the potential of quantitative ERCC1 mRNA expression to predict a minor or major histopathological response to neoadjuvant therapy with CDDP, 5-fluorouracil, and simultaneous radiation (36 Gy) in locally advanced, resectable esophageal cancers.
PATIENTS AND METHODS
Study Population, Demographic Data, and Neoadjuvant Therapy. All patients were recruited from an ongoing clinical trial on neoadjuvant radiochemotherapy for esophageal cancer during the period between August 2001 and August 2003. None of the patients had prior radio-and/or chemotherapy.
Thirty-nine consecutive patients (median age, 60 years; age range, 29 -72 years; gender, 30 men and 9 women) with locally advanced, resectable esophageal cancers (c T2-4 , N x , M 0 ) in good general health with an Eastern Cooperative Oncology Group performance status of 0 -1 and normal to moderate risk factors for esophageal surgery (14) were offered standardized neoadjuvant radiochemotherapy. Clinical staging was based on a barium swallow, endoscopic ultrasound, and computed tomography of chest and abdomen. Diagnostic laparoscopy was performed in all patients with adenocarcinomas to exclude peritoneal carcinomatosis. CDDP (20 mg/m 2 /day) was administered as a short-term infusion on days 1-5, and 5-fluorouracil (1000 mg/m 2 /day) was administered as a continuous infusion over 24 h on days 1-5. Radiation therapy was administered by linear accelerators with 10 -15-MV photons. Radiation therapy was simulated to encompass the tumor volume with 5-cm cephalocaudal-margins and 2-cm radial margins, and treatment ports were designed to include enlarged regional nodes based on computed tomography evaluation and endoscopic ultrasound. Radiation was delivered in daily fractions of 1.8 Gy (days 1-5, 8 -12, 15-19, and 22-26) to a total dose of 36 Gy using a multiple field technique. Surgical resection was performed 4 -5 weeks after completion of chemoradiation after clinical restaging using the same procedures as for staging, except for laparoscopy. Standardized transthoracic en bloc esophagectomy with two-field lymphadenectomy and reconstruction by gastric tube interposition with either left cervical or high intrathoracic anastomosis was performed in all patients (15) .
Three patients had to be excluded due to systemic progression during neoadjuvant therapy; these patients therefore did not proceed to surgical resection.
Therefore, 36 patients were included in the final analysis, and clinical data are summarized in Table 1 . Informed consent was obtained from each patient, and the scientific protocol was approved by the local ethics committee.
Histomorphological Grading of Tumor Regression. Because clinical response evaluation after neoadjuvant therapy for esophageal cancer was known to be highly inaccurate (16) , objective histopathological response analysis was applied using morphological criteria described by Junker et al. (17) .
The resected specimens were fixed in 10% formaldehyde, en bloc embedded in paraffin, and sectioned into 5-m slices that were stained with H&E. These sections were used for both histopathological staging according to the tumor-node-metastasis (TNM) classification system (18) and histomorphological evaluation of the effect of radiochemotherapy. The degree of histomorphological regression was classified into four categories: (a) grade I, Ͼ50% vital residual tumor cells; (b) grade II, 10 -50% vital residual tumor cells; (c) grade III, nearly complete response with Ͻ10% vital residual tumor cells; and (d) grade IV, complete response (pCR, ypT0). This analysis was performed by two independent staff pathologists who were blinded for all other clinical data (S. E. B. and H. P. D.). Regression grades III and IV were considered as major histomorphological response compared with grades I and II constituting minor histopathological response. Tissue Acquisition and RNA Isolation. Tissue samples from esophageal cancers and corresponding normal tissues were collected by endoscopic biopsy before starting neoadjuvant treatment. Samples were snap-frozen in liquid nitrogen and stored at Ϫ80°C until further processing. Samples were carefully chosen after control staining with H&E of individual biopsies.
Total cellular RNA was isolated using Trizol reagent (Life Technologies, Inc./GIBCO, Grand Island, NY) and quantitated at A 260/280 nm (Smart Spec; Bio-Rad, Hercules, CA).
Quantitative Reverse Transcription-PCR. Total cellular RNA (0.5 g) was reverse transcribed using an oligo(dT) 18 primer and Moloney murine leukemia virus reverse transcriptase (Clontech, Palo Alto, CA) according to the manufac- turer's recommendations. Placenta RNA from this kit was used to prepare standard curves. Twenty-five ng of cDNA were taken for real-time PCR using the Light Cycler System (Roche, Mannheim, Germany). Amplification was monitored by SYBR Green intercalation. For hot start, LC-DNA Master SYBR Green was preincubated with TaqStart antibody (Clontech) as suggested by the manufacturer. Briefly, the 10-l reaction volume contained 2 mM MgCl 2 and 1 M of each primer. Primers used for PCR amplification were chosen to encompass the intron between exon sequences. A 494-bp amplification product was obtained for ERCC1 mRNA, and a 276-bp product was obtained for ␤-actin mRNA. Primer sequences were as follows: ␤-actin, 5Ј-CAA-GAG-ATG-GCC-ACG-GCT (sense primer) and 5Ј-TCC-TTC-TGC-ATC-CTG-TCG-GCA [antisense primer (19) ]; and ERCC1, 5Ј-GTG-CAG-TCG-GCC-AGG-ATA-CAC (sense primer) and 5Ј-GTC-CTC-CTG-GAG-TGG-CCA-AG [antisense primer (20) ]. PCR conditions were 30 s at 95°C for initial denaturation, followed by 40 cycles of 0 s at 95°C, 20 s at 63°C, and 20 s at 72°C.
Product purity was controlled by melting point analysis, and PCR products were further analyzed electrophoretically on 2% agarose gels in a Horizon 58 electrophoresis chamber (GIBCO/BRL, Eggenstein, Germany) and visualized by ethidium bromide staining.
Absolute expression levels were calculated as ERCC1/␤-actin ratio in tumor and normal tissues, respectively. Relative mRNA expression levels (tumor/normal ratio) were calculated as (ERCC1/␤-actin in tumor)/(ERCC1/␤-actin in paired normal tissue).
Statistical Analysis. Gene expression levels were described using the median as a point estimator and the range of values. Cutoff values for discrimination of mRNA expression levels and histopathological response were derived from receiver operating curve data (area under the curve and the 95% confidence interval) according to Metz et al. (21) .
Associations between gene expression levels and clinicopathological parameters were evaluated using 2 , Kendall analysis, or Wilcoxon rank test and t test applying Fisher's exact testing for significance (Software Package SPSS for Windows, Version 11.0; SPSS, Chicago, IL). The level of significance was set to P Ͻ 0.05. Unless otherwise specified, P values are given for two-sided testing. ERCC1 mRNA and ␤-actin expression levels in three tumor measurements (ERCC1 1-3 and ␤-actin 1-3) from 36 patients. There were no significant differences in ERCC1 (P ϭ 0.61) and ␤-actin gene expression levels (P ϭ 0.58).
RESULTS

Distribution of
ERCC1 mRNA Expression Levels. ERCC1 mRNA expression was detected in all tumor (n ϭ 36) and corresponding normal epithelium (n ϭ 36) specimens. Median absolute ERCC1 mRNA expression levels standardized for ␤-actin were 1.02 (range
Fig. 2
Scattergram showing relative ERCC1 mRNA expression levels (T/N, ratio of tumor to normal tissue) in relation to minor and major histopathological response in resected specimens. ERCC1 expression levels of Ͼ1.09 are exclusively present in the group of minor histopathological response (sensitivity, 62.5%; specificity, 100%).
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In Fig. 2 , individual relative ERCC1 expression levels were blotted against the respective regression grades, and in Table 2 , absolute and relative ERCC1 mRNA expression levels are shown with the respective response grades for each individual patient. Cutoff values (21) for ERCC1 expression and histopathological response were calculated for an expression level of 1.09 (area under the curve, 0.74; 95% confidence interval, 0.58 -0.89) to identify minor histopathological response to neoadjuvant therapy.
There were no significant associations between dichotomized maximum cutoff values for ERCC1 expression (Յ1.09 or Ͼ1.09) and pT categories (P ϭ 0.9), pN categories (P ϭ 0.9), or grading of the primary tumor (P ϭ 0.4). In addition, when absolute ERCC1 mRNA expression levels in tumors were analyzed, no cutoff values could be identified to discriminate between minor and major histomorphological response.
Whereas 9 of 20 squamous cell cancers showed expression levels of Ͼ1.09, only 3 of 13 adenocarcinomas exhibited this class of expression levels. This association was only marginally significant by one-sided Fisher's exact test (P ϭ 0.05). Table 3 shows the association between major and minor histopathological response groups and dichotomized relative ERCC1 expression levels for the whole study group (n ϭ 36), and Table 4 shows the association between major and minor histopathological response groups and dichotomized relative ERCC1 expression levels for patients with squamous cell histology (n ϭ 23). The sensitivity for detection of a minor histopathological response was 62.5% with a specificity of 100% and was even higher for squamous cell cancers, with a sensitivity of 85.7% and a specificity of 100% (area under the curve, 0.89; 95% confidence interval, 0.76 -1). This association of dichotomized ERCC1 mRNA levels and histopathological response was highly significant for the whole group of tumors (P Ͻ 0.001) and the subgroup of squamous cell cancers (P Ͻ 0.001), as shown in Tables 2 and 3 . Subgroup analysis was not meaningful for adenocarcinomas due to the small sample size.
In summary, quantitative ERCC1 mRNA expression testing unequivocally identified 15 of 36 (42%) patients whose tumors will not exhibit a major histopathological response to the applied neoadjuvant radiochemotherapy with a specificity of 100%.
DISCUSSION
Because DNA is the primary cellular target for both chemotherapy-and radiation-induced damage, DNA repair efficiency could be a limiting factor for therapeutic response, preventing tumor cells from undergoing the process of apoptosis. In this study we have shown a significant association between ERCC1 mRNA expression levels in esophageal cancers and minor histopathological response to CDDP-based neoadjuvant radiochemotherapy.
In fact, quantitative ERCC1 mRNA expression testing by real-time reverse transcription-PCR unequivocally identified 15 of 36 patients whose tumors did not exhibit (specificity, 100%) a major histopathological response to the applied neoadjuvant radiochemotherapy. Experimental studies have demonstrated that increased ERCC1 levels are associated with removal of CDDP-induced strand adducts and relative CDDP resistance (22) . In addition, ERCC1 defective knockout mice are highly sensitive to DNA cross-linking agents (23) .
ERCC1 is also associated with radiation-induced DNA damage, although this mechanism is still poorly understood and is probably not associated with defects in the nucleotide excision repair pathway but rather mediated by radiation-induced DNA-protein cross-links and influenced by hypoxic conditions (7, 24) .
Association of ERCC1 expression with treatment response to CDDP-based chemotherapy has been shown in various tumor cell lines (25, 26) as well as solid tumors (6, 27) . Associations with clinical response as well as prognosis and altered ERCC1 mRNA expression have been demonstrated for neoadjuvant chemotherapy in locally advanced gastric cancers (11) . However, in advanced stages (IIB and IV) of non-small cell lung cancer, no association between ERCC1 levels and clinical response to CDDP-based chemotherapy could be demonstrated. A significant association was found with median survival time (13) . In contrast, osteosarcomas did not show evidence for an association between clinical response and expression levels of ERCC1 (28) .
Expression levels of genes involved in the metabolism of 5-fluorouracil might also contribute to improve prediction sensitivity of response in our treatment setting, as shown for thymidylate synthase in gastric cancer (11, 29) and thymidine phosphorylase in colon cancer (30) .
Clinical response evaluation after neoadjuvant therapy in solid tumors is highly inaccurate, as shown for esophageal cancer (16) , gastric cancer (31), and non-small cell lung cancer (32) . However, histopathological evaluation results in an objective analysis of remission with prognostic importance as convincingly demonstrated for non-small cell lung cancer (17, 33) . We applied histopathological criteria instead of inaccurate clinical restaging modalities for objective response evaluation in neoadjuvant-treated esophageal cancers and identified a significant association with minor histopathological response and dichotomized relative ERCC1 mRNA expression levels (P Ͻ 0.001).
The sensitivity is 62.5% for the whole group of esophageal cancers and 85.7% for squamous cell cancer group. More important, however, is the specificity of 100%, which would allow the unequivocal identification of a subset of patients with minor responses before treatment. We can expect, however, that the measured cutoff value in this pilot study might change with increasing numbers of patients analyzed in large prospective trials. Although median follow-up is too short to allow a meaningful evaluation between the association of ERCC1 expression levels and survival in our protocol, it has been demonstrated in the past that only patients with major histopathological responses benefit from this type of treatment independent of the applied protocol (3) (4) (5) .
The present, still early results of this ongoing study are promising, and it appears that we might expect to unequivocally identify approximately one-third of patients who fulfill the criteria for neoadjuvant treatment for locally advanced esophageal cancer but will not benefit from our treatment protocol. This might prevent our patients from expensive, noneffective, and potentially harmful therapies and lead to a more individualized type of multimodal treatment in the near future.
